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We evaluated the ability of epitope-blocking enzyme-linked immunosorbent assays (ELISAs) to detect West
Nile virus (WNV) antibodies in domestic mammals. Sera were collected from experimentally infected horses,
cats, and pigs at regular intervals and screened in ELISAs and plaque reduction neutralization tests. The
diagnostic efficacies of these techniques were similar.
West Nile virus (WNV) is a single-stranded, positive-sense
RNA virus in the genus Flavivirus, family Flaviviridae (3). It is
a member of the Japanese encephalitis virus (JEV) complex,
which also includes JEV, St. Louis encephalitis virus (SLEV),
Murray Valley encephalitis virus, and Koutango virus (KOUV)
(12). WNV is transmitted in natural cycles between mosquitoes
and birds, and humans and horses are incidental hosts (11).
WNV has a wide geographic distribution, recently including
North America. The initial outbreak of WNV in North Amer-
ica took place in New York in 1999, with mortality observed in
humans, horses, and numerous species of wild birds (6, 8, 15).
WNV activity has now been detected throughout most of the
United States, and clinical infections in thousands of humans
and horses have been reported. WNV is known to infect many
other mammals, including cats, dogs, donkeys, goats, sheep,
pigs, cows, rabbits, squirrels, and bats (7, 11, 13).
Serologic diagnosis of WNV infections in vertebrates can be
achieved by the plaque reduction neutralization test (PRNT)
and the hemagglutination inhibition assay (1). However, these
assays are laborious and therefore not ideal for large-scale
routine testing of sera. In contrast, enzyme-linked immunosor-
bent assays (ELISAs) provide rapid diagnostic and surveillance
techniques to monitor WNV activity. We have previously re-
ported the application of epitope-blocking ELISAs for the
detection of WNV antibodies in multiple avian species (2, 9).
Here, the ability of the blocking ELISAs to detect WNV an-
tibodies in selected species of domestic mammals was evalu-
ated.
Protocols used to prepare ELISA coating antigen and per-
form blocking ELISAs have been described previously (2).
Five monoclonal antibodies (MAbs) were tested in blocking
assays, and the production and characterization of these MAbs
have been described elsewhere (10, 16, 17). Briefly, MAb 2B2
is WNV and KOUV specific, MAb 3.1112G is WNV specific,
MAb 6B5A-2 is SLEV specific, and MAbs 3H6 and 6B6C-1 are
flavivirus group reactive. All MAbs detect E protein epitopes,
with the exception of MAb 3.1112G, which detects an NS1
epitope. MAb 6B6C-1 was labeled with horseradish peroxi-
dase; all other MAbs were unlabeled. To calculate the percent
inhibition of MAb binding in blocking assays, the following
formula was used: 100  [(TS  B)/(CS  B)]  100. TS
denotes the optical density (OD) of the test sample, CS denote
the OD of the control serum, and B denotes the background
OD. Previously, an inhibition value 30% was shown to indi-
cate the presence of viral antibodies in avian sera (2), and the
same diagnostic criterion was used here.
Nine horses (H1 to H9), four cats (C1 to C4), and four pigs
(P1 to P4) were experimentally inoculated with WNV (NY-99)
via infected Aedes albopictus mosquitoes. Prior to inoculation,
all animals were screened by PRNT for neutralizing antibodies
against WNV and SLEV and were shown to be negative. An-
imals were then relocated to a BL-3 containment facility,
where virus inoculations were performed. Horses were sam-
pled at 7, 14, 21, and 28 days postinfection (p.i.), unless they
were euthanized earlier. Cats were sampled at 7, 14, and 28
days p.i., and pigs were sampled at 7, 14, and 21 days p.i.
Animals were also bled immediately before inoculation (0 days
p.i.). These animals are being used in WNV experimental
infection trials. Details of that study, including the viremia
profile and course of clinical disease (if any) of each animal,
will be presented elsewhere (D. R. Bowen, unpublished data).
Serum was obtained from an additional horse (H10) that was
immunized with a recombinant DNA vaccine expressing the
WNV prM and E genes prior to WNV challenge (5). Fifteen
weeks postimmunization, the horse was challenged with WNV
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via infected A. albopictus mosquitoes, and serum was collected
31 days later.
First, the ability of the blocking ELISA to detect antibodies
in the nonvaccinated WNV-infected horses was evaluated.
Most-promising results were obtained in assays utilizing MAbs
3.1112G and 6B6C-1, with antibodies detected in all sera col-
lected at14 days p.i. (Table 1). These findings correlated well
with the PRNT data. That is, all sera exhibiting neutralizing
titers at a 90% plaque reduction level (PRNT90) were positive
in ELISAs. For MAb 3.1112G, the mean inhibition values for
sera collected at 14, 21, and 28 days p.i. were 55.6, 67.9, and
75.4%, respectively. For MAb 6B6C-1, the mean inhibition
values for sera collected at 14, 21, and 28 days p.i. were 53.1,
63.5, and 70.0%, respectively. ELISAs that utilized MAbs 2B2
and 3H6 were also effective, with antibodies detected in most
horses at 14 days p.i. and in all horses at 21 days p.i. Serum
from the vaccinated horse was positive in all assays using E-
specific MAbs, revealing that the horse had generated an im-
mune response prior to WNV challenge (Table 1). In contrast,
the serum was negative in the ELISA that utilized MAb
3.1112G. However, the inhibition value was just below the
diagnostic criterion, suggesting that a limited amount of MAb-
binding inhibition occurred. It is possible that vaccination did
not provide sterile immunity and that a low level of WNV
replication occurred after challenge.
All PRNT90-positive cat sera were positive in blocking assays
that utilized MAbs 3H6 and 6B6C-1 (Table 2). ELISAs using
these MAbs also detected antibodies in two PRNT90-negative
sera. However, both sera exhibited low PRNT titers at a plaque
reduction level of 80% (data not shown). Assays using MAbs
3.1112G and 2B2 were also effective, with antibodies detected
in three and four cats, respectively, at 21 days p.i. Analysis of
the pig sera revealed that all specimens collected at 28 days p.i.
were positive in ELISAs utilizing MAbs 3.1112G and 6B6C-1,
while three were positive in assays using MAbs 2B2 and 3H6
(Table 2). In contrast, only two sera collected on day 28 were
PRNT90 positive, although one of the PRNT90-negative sam-
ples exhibited a low PRNT80 titer (data not shown). All
PRNT90-positive pig sera collected at 14 days p.i. were positive
in assays using MAb 6B6C-1, while the two PRNT90-positive
sera collected at 7 days p.i. were negative in all assays.
To further validate the diagnostic efficacy of the blocking
ELISAs, sera from five SLEV-infected cows (CO1 to CO5)
were tested. Specimens were collected from domestic cows
during a serological survey in Chiapas, Mexico, in 2001. All
sera contained detectable levels of neutralizing antibodies
against SLEV (Table 2). Antibodies were detected in four cows
in assays using the flavivirus group-reactive MAbs 3H6 and
6B6C-1 and in three cows with the SLEV type-specific MAb
6B5A-2. All sera were negative when the WNV MAbs, 2B2
and 3.1112G, were used. One serum sample failed to block
MAb binding in all assays.
The ability of the blocking-ELISA technique to detect anti-
bodies against various other flaviviruses of the Americas was
determined. Hyperimmune mouse ascitic fluids (HIMAFs)
containing antibodies against WNV, SLEV, Ilheus virus (ILHV),
Bussuquara virus (BSQV), or Powassan virus (POWV) were
tested in ELISAs using MAb 6B6C-1. All HIMAFs signifi-
cantly inhibited MAb binding. The inhibition values were
58.9% for the WNV HIMAF, 70.9% for the SLEV HIMAF,
68.1% for the ILHV HIMAF, 38.7% for the BSQV HIMAF,
and 60.2% for the POWV HIMAF. The ability to detect
POWV antibodies is of particular interest, as phylogenetic
studies have shown that the tick-borne and mosquito-borne
flaviviruses are evolutionarily diverse and separated into two
distinct clades (3). Therefore, this assay can potentially be
exploited to identify antibodies against many different flavivi-
TABLE 1. Percent inhibition of MAbs by blocking ELISA using
sera from WNV-infected horsesc
Serum
sourcea
Day post-
challenge
WNV PRNT90
titer
% Inhibition of binding
of MAbb:
2B2 3.1112G 3H6 6B6C-1
H1 0 10 0 4.5 3.8 4.1
H2 0 10 3.4 2.7 3.4 5.0
H3 0 10 0 1.3 1.7 3.8
H4 0 10 0 2.5 4.7 5.6
H5 0 10 5.2 0.6 2.6 2.6
H6 0 10 0 2.9 4.0 4.2
H7 0 10 11.7 11.0 1.2 0
H8 0 10 1.4 0 3.0 0
H9 0 10 3.3 5.2 0.3 0
Mean 2.8 3.4 2.7 2.8
H1 7 10 0 0 0.8 0.2
H2 7 10 4.9 0 0 0
H3 7 10 4.2 1.6 0 16.2
H4 7 10 6.4 5.6 10.3 13.9
H5 7 10 10.9 0 0 18.6
H6 7 10 10.0 7.4 1.3 4.1
H7 7 10 0 0.8 0 0
H8 7 10 13.0 6.6 0 0
H9 7 10 0 3.0 3.3 0
Mean 5.5 2.8 1.7 5.9
H1 14 160 45.3 34.3 34.8 34.6
H2 14 80 31.0 34.1 20.9 39.9
H3 14 160 24.1 55.6 34.5 56.9
H4 14 80 18.0 64.3 35.0 57.5
H5 14 160 57.0 57.6 39.6 65.8
H6 14 160 36.6 58.7 35.7 58.1
H7 14 80 8.7 46.0 27.1 56.0
H8 14 >160 30.6 69.0 29.6 49.8
H9 14 >160 45.0 80.5 47.8 59.1
Mean 32.9 55.6 33.9 53.1
H1 21 160 58.0 69.7 51.5 57.9
H2 21 40 36.0 60.7 38.7 57.5
H3 21 40 34.4 64.7 50.2 61.9
H4 21 40 41.1 75.2 52.7 72.3
H5 21 40 76.7 69.3 43.9 68.0
Mean 49.2 67.9 47.4 63.5
H1 28 >160 48.5 74.0 54.5 65.6
H2 28 >160 60.5 72.8 53.4 73.6
H4 28 80 40.0 79.5 54.2 70.8
Mean 49.7 75.4 54.0 70.0
H10d 31 320 77.2 28.8 44.3 66.2
a All sera were diluted 10-fold and tested in duplicate. Control serum consisted
of commercially available normal horse serum (Vector Laboratories, Burlin-
game, Calif.) or a pooled suspension of sera collected from H1 to H9 at day 0.
b MAb 2B2 is WNV and KOUV specific; MAb 3.1112G is WNV specific;
MAbs 3H6 and 6B6C-1 are flavivirus group reactive.
c Boldface inhibition values (30%) and boldface PRNT titers (20) were
considered significant.
d Horse was vaccinated prior to virus challenge.
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ruses. Serum from an uninfected mouse was used as control
serum when calculating the percentages of inhibition.
To ascertain the sensitivity of the ELISAs, 15 randomly
selected samples were tested at multiple dilutions against
MAbs 3.1112G and 6B6C-1. Sera were serially twofold diluted
by using a starting dilution of 1:10, and HIMAFs were serially
twofold diluted by using a starting dilution of 1:5,000. Both
MAbs worked particularly well when used to screen sera from
nonvaccinated horses. The six specimens tested exhibited
ELISA end point titers between 80 and 320 (Table 3). In assays
that utilized MAb 6B6C-1, all cat, pig, and cow sera tested
displayed ELISA end point titers 160. The WNV and SLEV
HIMAFs significantly inhibited the binding of MAb 6B6C-1 at
dilutions 40,000.
Therefore, the blocking ELISA reliably detected flavivirus
antibodies in several evolutionarily diverse species of mam-
mals. Indeed, similar assays have been exploited to detect
serum antibodies against WNV (subtype Kunjin virus) in lab-
oratory-infected rabbits (9). The present study demonstrated
the concordance of ELISA and PRNT. Occasional disparities
were observed, but this was not unexpected because the two
assays do not necessarily detect the same antibody types. Fur-
thermore, neutralizing antibodies have a greater longevity than
nonneutralizing antibodies (4), and this may explain why one
cow tested negative by ELISA. Comparative analyses of im-
munoglobulin M antibody capture ELISAs and PRNTs re-
vealed occasional discrepancies in arbovirus diagnosis (14).
However, blocking ELISAs provide a more rapid and less
expensive means to detect WNV infections than PRNTs, so
these assays would greatly facilitate WNV surveillance studies
in the United States.
This study was supported by grant U50 CCU820510 from the Cen-
ters for Disease Control and Prevention.
We thank Nicholas Komar, Stanley Langevin, and Armando Ulloa
for providing the cow sera.
REFERENCES
1. Beaty, B. J., C. H. Calisher, and R. E. Shope. 1989. Arboviruses, p. 797–855.
In N. J. Schmidt and R. W. Emmons (ed.), Diagnostic procedures for viral,
rickettsial, and chlamydial infections, 6th ed. American Public Health Asso-
ciation, Washington, D.C.
2. Blitvich, B. J., N. L. Marlenee, R. A. Hall, C. H. Calisher, R. A. Bowen, J. T.
TABLE 2. Percent inhibition of MAbs by blocking ELISA using
sera from WNV-infected cats and pigs and SLEV-infected cowsd
Serum
sourcea
Day post-
challenge
PRNT90
titer for:
% Inhibition of binding
of MAbb:
WNV SLEV 2B2 3.1112G 3H6 6B6C-1 6B5A-2
Cat
C1 7 10 —c 3.8 0 1.6 1.8 —
C2 7 10 — 1.8 8.4 0 11.0 —
C3 7 10 — 3.8 6.4 0 0 —
C4 7 10 — 0 0 0 0 —
C1 14 10 — 23.5 0 50.8 55.7 —
C2 14 40 — 36.8 7.5 48.1 49.0 —
C3 14 10 — 10.3 28.4 47.1 47.2 —
C4 14 10 — 12.9 26.5 47.1 39.6 —
C1 21 40 — 58.7 17.9 57.1 66.2 —
C2 21 160 — 61.8 41.1 61.7 60.9 —
C3 21 10 — 31.0 41.7 55.2 63.6 —
C4 21 40 — 49.0 43.4 55.2 56.5 —
Pigs
P1 0 10 — 4.4 0 0 0 —
P2 0 10 — 0 0 0 2.8 —
P3 0 10 — 0 0 0 1.8 —
P4 0 10 — 0 0 0 2.3 —
P1 7 20 — 0 3.1 1.9 8.0 —
P2 7 10 — 8.5 11.0 4.0 2.3 —
P3 7 20 — 2.6 8.5 0 6.2 —
P4 7 10 — 3.5 7.7 14.2 0 —
P1 14 40 — 13.7 12.5 24.8 36.5 —
P2 14 10 — 29.6 32.3 22.0 38.2 —
P3 14 20 — 17.9 34.4 13.4 37.4 —
P4 14 10 — 0 19.8 7.6 15.5 —
P1 28 40 — 38.6 42.6 46.5 66.2 —
P2 28 10 — 48.7 50.3 43.2 66.1 —
P3 28 10 — 46.9 53.4 43.9 71.8 —
P4 28 10 — 6.8 36.8 22.0 33.6 —
Cows
CO1 NAe 10 >320 0 0 64.6 71.9 48.5
CO2 NA 10 20 0 0 0 0 0
CO3 NA 10 40 9.7 0 71.7 76.6 54.4
CO4 NA 10 160 0 0 85.3 86.0 52.8
CO5 NA 10 40 2.8 0 65.1 73.1 0
a All sera were diluted 10-fold and tested in duplicate. Control serum was
obtained from an uninfected animal(s) of the same species. Control cat sera
consisted of a pooled suspension of sera collected from C1 to C4 on day 0.
Control pig sera consisted of commercially available normal pig serum (Vector
Laboratories) or a pooled suspension of sera collected from P1 to P4 on day 0.
Control cow serum was obtained from a cow that was PRNT negative for SLEV
and WNV.
b MAb 2B2 is WNV and KOUV specific; MAb 3.1112G is WNV specific;
MAbs 3H6 and 6B6C-1 are flavivirus group reactive; MAb 6B5A-2 is SLEV
specific, and assays utilizing this MAb were performed with coating antigen
prepared from SLEV-infected cells.
c —, not tested.
d Boldface inhibition values (30%) and boldface PRNT titers (20) were
considered significant.
e NA, not applicable.
TABLE 3. Determination of antibody titers in sera and
ascitic fluids by blocking ELISA
Sample
source
Day post-
challenge
Blocking-ELISA
titer for MAb:
PRNT
titer for:
3.1112G 6B6C-1 WNV SLEV
H1 21 80 160 160 —a
H2 21 160 80 40 —
H4 21 160 160 40 —
H1 28 160 160 160 —
H2 28 160 320 160 —
H4 28 160 80 80 —
H10 31 10 10,240 320 —
C2 21 80 640 160 —
C3 21 20 640 10 —
P1 28 40 160 40 —
P3 28 80 320 10 —
CO4 NAb 10 160 10 160
CO5 NA 10 320 10 40
WNV HIMAF NA — 80,000 — —
SLEV HIMAF NA — 40,000 — —
a —, not tested.
b NA, not applicable.
2678 NOTES J. CLIN. MICROBIOL.
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
Roehrig, N. Komar, S. A. Langevin, and B. J. Beaty. 2003. Epitope-blocking
enzyme-linked immunosorbent assays for detection of serum antibodies to
West Nile virus in multiple avian species. J. Clin. Microbiol. 41:1041–1047.
3. Burke, D. S., and T. P. Monath. 2001. Flaviviruses, p. 1043–1126. In D. M.
Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams
and Wilkins, Philadelphia, Pa.
4. Casals, J. 1973. Arbovirus infections, p. 99–117. In J. R. Paul, and C. White
(ed.), Serological epidemiology. Academic Press, New York, N.Y.
5. Davis, B. S., G.-J. J. Chang, B. Cropp, J. T. Roehrig, D. A. Martin, C. J.
Mitchell, R. Bowen, and M. L. Bunning. 2001. West Nile virus recombinant
DNA vaccine protects mouse and horse from virus challenge and expresses
in vitro a noninfectious recombinant antigen that can be used in enzyme-
linked immunosorbent assays. J. Virol. 75:4040–4047.
6. Eidson, M., N. Komar, F. Sorhage, R. Nelson, T. Talbot, F. Mostashari, and
R. McLean. 2001. Crow deaths as a sentinel surveillance system for West
Nile virus in the northeastern United States, 1999. Emerg. Infect. Dis. 7:615–
620.
7. Garmendia, A. E., H. J. Van Kruiningen, and R. A. French. 2001. The West
Nile virus: its recent emergence in North America. Microbes Infect. 3:223–
229.
8. Gubler, D. J., G. L. Campbell, R. Nasci, N. Komar, L. Petersen, and J. T.
Roehrig. 2000. West Nile virus in the United States: guidelines for detection,
prevention, and control. Viral Immunol. 13:469–475.
9. Hall, R. A., A. K. Broom, A. C. Hartnett, M. J. Howard, and J. S. Mackenzie.
1995. Immunodominant epitopes on the NS1 protein of MVE and KUN
viruses serve as targets for a blocking ELISA to detect virus-specific anti-
bodies in sentinel animal serum. J. Virol. Methods 51:201–210.
10. Hall, R. A., B. H. Kay, G. W. Burgess, P. Clancy, and I. D. Fanning. 1990.
Epitope analysis of the envelope and non-structural glycoproteins of Murray
Valley encephalitis virus. J. Gen. Virol. 71:2923–2930.
11. Hayes, C. G. 1988. West Nile fever, p. 59–88. In T. P. Monath (ed.), The
arboviruses: epidemiology and ecology. CRC Press Inc., Boca Raton, Fla.
12. Heinz, F. X., M. S. Collett, R. H. Purcell, E. A. Gould, C. R. Howard, M.
Houghton, R. J. M. Moormann, C. M. Rice, and H.-J. Theil. 2000. Family
Flaviviridae, p 859–878. In M. H. V. van Regenmortel, C. M. Fauquet,
D. H. L. Bishop, E. B. Carstens, M. K. Estes, S. M. Lemon, J. Maniloff, M. A.
Mayo, D. J. McGeoch, C. R. Pringle, and R. B. Wickner (ed.), Virus taxon-
omy. Seventh report of the International Committee for the Taxonomy of
Viruses. Academic Press, San Diego, Calif.
13. Komar, N. 2000. West Nile viral encephalitis. Rev. Sci. Technol. 19:166–176.
14. Martin, D. A., D. A. Muth, T. Brown, A. J. Johnson, N. Karabatsos, and J. T.
Roehrig. 2000. Standardization of immunoglobulin M capture enzyme-
linked immunosorbent assays for routine diagnosis of arboviral infections.
J. Clin. Microbiol. 38:1823–1826.
15. Nash, D., F. Mostashari, A. Fine, J. Miller, D. O’Leary, K. Murray, A.
Huang, A. Rosenberg, A. Greenberg, M. Sherman, S. Wong, and M. Layton.
2001. The outbreak of West Nile virus infection in the New York City area
in 1999. N. Engl. J. Med. 344:1807–1814.
16. Roehrig, J. T., J. H. Mathews, and D. W. Trent. 1983. Identification of
epitopes on the E glycoprotein of Saint Louis encephalitis virus using mono-
clonal antibodies. Virology 128:118–126.
17. Scherret, J. H., M. Poidinger, J. S. Mackenzie, A. K. Broom, V. Deubel, W. I.
Lipkin, T. Briese, E. A. Gould, and R. A. Hall. 2001. The relationships
between West Nile and Kunjin viruses. Emerg. Infect. Dis. 7:697–705.
VOL. 41, 2003 NOTES 2679
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
